Emyria Secures First DVA Treatment Approvals as Veteran Referrals Exceed 40
The Australian psychedelic-assisted therapy provider has reported record quarterly revenue of $1.42 million, expanded its national clinic network and received ...
The Australian psychedelic-assisted therapy provider has reported record quarterly revenue of $1.42 million, expanded its national clinic network and received ...
Australian psychedelic medicine company Emyria Limited (ASX: EMD) has been selected by the US Food and Drug Administration (FDA) to ...
Emyria (ASX: EMD) has released its June 2026 quarterly update, highlighting strong revenue growth, national clinic expansion and encouraging early ...
Psychedelics.media delivers trusted news, intelligence, and insights for the global psychedelic medicine industry.
